What's in Kura Oncology, Inc.'s pipeline?

Kura Oncology, Inc. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Kura Oncology, Inc.'s portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Astellas Pharma Global Development, Inc., AstraZeneca, Celgene, Centre Hospitalier Universitaire Dijon.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/kura-oncology-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Kura Oncology, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kura Oncology, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Cytarabine (Ara-C)	Cytarabine (Ara-C)	phase 3	Nucleoside analog; antimetabolite	DNA polymerase; thymidylate synthase	Oncology

Therapeutic area mix

Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Astellas Pharma Global Development, Inc. · 1 shared drug class
AstraZeneca · 1 shared drug class
Celgene · 1 shared drug class
Centre Hospitalier Universitaire Dijon · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 shared drug class
Eisai Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kura Oncology, Inc.:

Cite this brief

Drug Landscape (2026). Kura Oncology, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kura-oncology-inc. Accessed 2026-05-17.